Is BGMD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

436 people get BGMD articles and Market Currents by email alert.

Get email alerts on BGMD »

HEADLINES:

Emerging Biomarker Companies Redux: Positioned For Growth
Rod Raynovich • Wed, May 15 • 4 Comments
BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire (May 10, 2013)
BG Medicine's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer

GlobeNewswire (May 9, 2013)
BG Medicine Reports 2013 First Quarter Financial Results

GlobeNewswire (May 9, 2013)
Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, to Reduce Hospital Readmissions

GlobeNewswire (May 8, 2013)
BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013

GlobeNewswire (May 2, 2013)
BG Medicine Welcomes CE Mark for Galectin-3 Test

GlobeNewswire (Apr 10, 2013)
BG Medicine's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13
BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook

GlobeNewswire (Mar 13, 2013)
BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo

GlobeNewswire (Mar 6, 2013)
BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, March 13, 2013

GlobeNewswire (Mar 6, 2013)
BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

GlobeNewswire (Feb 27, 2013)
BG Medicine, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
3 Small Cap Biotech Plays Potentially Facing Cash-Flow Issues
Matt Schilling • Mon, Feb 18 • 22 Comments
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option

GlobeNewswire (Jan 30, 2013)
BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock

GlobeNewswire (Jan 25, 2013)
BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire (Jan 24, 2013)
BG Medicine, Inc. Enters Into $12 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

GlobeNewswire (Jan 24, 2013)

To learn more about Seeking Alpha Pro, click here.

BG Medicine: This Forgotten IPO Is A Hidden Gem
Robert Fabian • Thu, Dec 27, 2012 • 9 Comments
BG Medicine Prices IPO After Halving Original Price Range
SA Editor Mohit Manghnani • Sun, Feb 6, 2011
Biotech IPO: BG Medicine Competes With Abbott Laboratories, JNJ In Molecular Diagnostics
SA Editors • Sun, Dec 16, 2007

Emerging Biomarker Companies Redux: Positioned For Growth
Rod Raynovich • Wed, May 15 • 4 Comments
3 Small Cap Biotech Plays Potentially Facing Cash-Flow Issues
Matt Schilling • Mon, Feb 18 • 22 Comments
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Wed, Dec 12, 2012 • 4 Comments
2 Biotech Companies To Consider In The Wake Of Positive Developments
Matt Schilling • Tue, Dec 11, 2012 • 2 Comments
Biotech Weekend Recap: Short Week, Major Rally
Brian L. Wilson • Sun, Nov 25, 2012 • 10 Comments
Profiting From The Trend Towards Point Of Care Diagnostics
Paul Nouri • Tue, Nov 20, 2012 • 13 Comments
4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce
MarketScanners • Tue, Nov 20, 2012 • 11 Comments
3 Small Cap Bio-Pharmas Offering Good Upside Potential
Scott Matusow • Tue, Nov 20, 2012 • 33 Comments
Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
Rod Raynovich • Thu, Nov 15, 2012
China Biotech In Review: U.S. Medical Device Makers Turn Attention To 2nd And 3rd Tier Cities
ChinaBio Today • Sun, Oct 28, 2012 • 1 Comment
4 Undervalued Cash-Heavy Stocks With Room To Run Higher
R.S. Analytics • Tue, Oct 9, 2012 • 5 Comments
7 Cash Loaded Healthcare Stocks With Strong Analyst Confidence
ZetaKap • Wed, Jun 20, 2012 • 2 Comments
Notable Micro Cap Insider Buys Last Week
Gutone • Mon, May 28, 2012 • 4 Comments
6 Healthcare Stocks With Great Liquidity And Strong Buy Ratings
ZetaKap • Mon, May 7, 2012 • 12 Comments
Emerging Biomarker Diagnostics: BGMedicine And Vermillion
Rod Raynovich • Wed, Apr 4, 2012 • 4 Comments
Hedge Funds Love These 9 Rebounding Biotech Stocks
Kapitall • Sat, Jan 7, 2012 • 3 Comments
20 Micro-Cap Stocks Being Snapped Up By Hedge Funds
Kapitall • Thu, Dec 15, 2011
Biotech IPO Class of 2011 Takes Drubbing
The Burrill Report • Sun, Aug 14, 2011
Surprisingly, Smaller Stocks Went Up When the Market Dropped
Value Research • Wed, Aug 10, 2011 • 2 Comments

BG Medicine's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
BG Medicine's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13

BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire (May 10, 2013)
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer

GlobeNewswire (May 9, 2013)
BG Medicine Reports 2013 First Quarter Financial Results

GlobeNewswire (May 9, 2013)
Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, to Reduce Hospital Readmissions

GlobeNewswire (May 8, 2013)
BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013

GlobeNewswire (May 2, 2013)
BG Medicine Welcomes CE Mark for Galectin-3 Test

GlobeNewswire (Apr 10, 2013)
BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook

GlobeNewswire (Mar 13, 2013)
BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo

GlobeNewswire (Mar 6, 2013)
BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, March 13, 2013

GlobeNewswire (Mar 6, 2013)
BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

GlobeNewswire (Feb 27, 2013)
BG Medicine, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option

GlobeNewswire (Jan 30, 2013)
BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock

GlobeNewswire (Jan 25, 2013)
BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire (Jan 24, 2013)
BG Medicine, Inc. Enters Into $12 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

GlobeNewswire (Jan 24, 2013)
BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

GlobeNewswire (Jan 2, 2013)
BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

GlobeNewswire (Dec 11, 2012)
BG Medicine, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference

GlobeNewswire (Nov 20, 2012)
BG Medicine Reports Third Quarter 2012 Financial Results and Provides Business Update

GlobeNewswire (Nov 13, 2012)
BG Medicine Outlines New Commercial Strategy

GlobeNewswire (Nov 13, 2012)

BGMD vs. ETF Alternatives

Company Description

Currently, there's no company description for BGMD.

Sector: Healthcare

Industry: Medical Laboratories & Research

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 9:45 AM BG Medicine (BGMD): Q1 EPS of -$0.21 beats by $0.06. Revenue of $888K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 10, 10:31 AM BG Medicine (BGMD +3.6%) trades up after announcing earlier that partner Abbott (ABT +0.2%) has obtained a CE Mark for its Galectin-3 assay run on the Architect immunochemistry platform. The Galectin-3 assay is an indicator that assesses the risk for readmission in heart failure. BGMD is partnering with four diagnostic instrument manufacturers to commercialize automated versions of the test, making it available in several European countries, pending country registration. Comment! [Healthcare, On the Move, Global & FX]
Wednesday, March 13, 10:19 AM BG Medicine (BGMD +14%) ramps higher after beating Q4 EPS estimates on a narrower-than-expected loss. Revenue jumped nearly 250% Y/Y, driven largely by increased sales of its BGM Galectin-3(R) test, with product margins increasing 10% over the same period from 60% to 70%. Net losses also decreased by 38% Y/Y from $4.7M to $2.9M, primarily from an adjustment of accrued R&D expenses. Comment! [Healthcare, Earnings, On the Move]
Wednesday, March 13, 9:10 AM Premarket gainers: BGMD +15%. SUMR +10%. PPHM +5%.
Losers: SPPI -36%. VELT -32%. ASMI -13%. EXPR -13%. TEU -10%. DOLE -7%. WFR -6%. Comment! [On the Move]
Wednesday, March 13, 7:51 AM BG Medicine (BGMD): Q4 EPS of -$0.14 beats by $0.18. Revenue of $1.07M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, February 27, 10:39 AM BG Medicine (BGMD +11%) ramps higher this morning after announcing the publication of two studies demonstrating the benefit of repeated galectin-3 testing as a tool in the assessment of patients with heart failure. The studies demonstrate that periodic evaluation of galectin-3 levels can help clinicians identify those at greater risk of unplanned hospital admission and cardiovascular morbidity and mortality. Comment! [Healthcare, On the Move]
Friday, January 25, 12:45 PM Midday top 10 gainers: EFII +15%. OSK +15%. SHIP +15%. SYNA +15%. LSCC +14%. NFLX +14%. QLGC +13%. BDR +13%. CIMT +13%. CRUS +12%.
Midday top 10 Losers: NFBK -27%. ZN -26%. SCSS -18%. SCSC -15%. BGMD -15%. CTRP -13%. HTCH -11%. EGHT -10%. ARWR -8%. MSL -7%. Comment! [On the Move]
Friday, January 25, 9:10 AM Premarket gainers: INFA +10%. TPX +10%. ECTE +9%. OSK +8%. STP +6%. THLD +7%. SNE +6%.
Losers: SCSS -15%. BGMD -15%. EGHT -10%. SFL -8%.
1 Comment [On the Move]
Friday, January 25, 8:02 AM BG Medicine (BGMD) -10% premarket after announcing a secondary to price this morning and its intention to purchase up to $12M of its stock from a big holder, Aspire Capital. Comment! [Healthcare, On the Move]
Thursday, January 3, 12:45 PM Midday top 10 gainers: SPWR +38%. VISN +30%. MDCI +20%. FORD +20%. BGMD +19%. TSL +19%. CRDC +19%. FOLD +19%. TELK +18%. JASO +16%.
Midday top 10 Losers: LPH -73%. ALLT -23%. MLNX -14%. FDO -12%. AMPL -12%. TRIT -11%. PKT -10%. SSI -9%. LODE -9%. HPJ -9%. 1 Comment [On the Move]
Thursday, January 3, 9:10 AM Premarket gainers: BGMD +22%. SPWR +16%. ALU +10%. CBMX +10%. FOLD +8%. TASR +6%. LDK +6%. ZGNX +5%.
Losers: MLNX -18%. ALLT -10%. FDO -10%. KERX -6%. BIIB -6%. Comment! [On the Move]
Thursday, January 3, 8:28 AM BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first automated version of the company's Galectin-3 blood test for improving the management of heart conditions. BG is working with four partners to commercialize the test, including Abbott Labs (ABT) and Siemens (SI). The EU approval comes just a week after SA author Robert Fabian called BG Medicine a "hidden gem." (PR) Comment! [Healthcare, On the Move]
Wednesday, January 2, 5:37 PM After-hours top gainers, as of 5:15 p.m.: BGMD +14%. KYAK +8%. SZYM +6%. LNDC +4%. NAVB +3%.
After-hours top losers: MLNX -16%. RMBS -12%. ESIO -8%. AUO -6%. OME -4%. 1 Comment [On the Move]
Wednesday, December 12, 2012, 9:10 AM Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. BGMD +10%.
Losers: RSOL -16%. CIE -11%. MCP -6%. Comment! [On the Move]
Tuesday, December 11, 2012, 6:10 PM After-hours top gainers, as of 5:15 p.m.: RTEC +8%. DLB +6%. MCBC +4%. BGMD +4%. GEO +3%.
After-hours top losers: GEOS -12%. CIE -10%. EXAR -7%. NTSP -7%. ALXA -7%. 1 Comment [On the Move]
Tuesday, December 11, 2012, 12:45 PM Midday top 10 gainers: BGMD +146%. SOMX +75%. ACUR +56%. TNS +43%. ULBI +18%. MEAD +16%. ESYS +15%. SZYM +14%. GTXI +13%. CLWR +12%.
Midday top 10 Losers: CBMX -11%. ESIO -11%. AMCN -9%. SEV -9%. GGAL -8%. SPW -8%. TELK -7%. [[JW-A]] -7%. MGLN -7%. SXC -7%. 2 Comments [On the Move]

Motiv8
Due to a lack of any news for BGMD lately, I can say we're set for an interesting day of trading. Actual sales of product recorded. $BGMD
May 8, 9:18 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for March 13 2013 | $ASML $BGMD $GLUU $HTWR $NPSH $PERI $YNDX http://stks.co/r5Ej
Mar 13, 9:39 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Mid-Day Charts & Technical Analysis: $SHLD, $VHC, $BGMD & Others | http://bit.ly/Z0tCiZ
12/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$BGMD short term PT opinion call complete, $1.45 - $1.55 hit $1.58 today
11/23/12
Reply (2)

• !Report Abuse
View all 2 replies
sheldond: That was a pretty prescient call. Too bad I didn't put more on this oppotunity. Good Call!
11/24/12
• !Report Abuse
Scott Matusow: Thanks Sheldon --we all need more of these! Now I have to make sure I don't make bad calls, u know like the election prediction I made! lol!
11/24/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$BGMD first target just hit - $1.45
11/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$LGND $19.05 alerted at $16.60 $BGMD $1.35 alerted at $1.05 $AVEO $6.80 alerted at $6.60 $FOLD $4.85 alerted at $4.35
11/23/12
Reply (4)

• !Report Abuse
View all 4 replies
blakhalo: CPRX $.52 alerted at $1.88 -/+
11/26/12
• !Report Abuse
Scott Matusow: blak, u must lose money in the market -- I also gave a price target of $2.25 after financing -- that's on traders, now learn to make money
11/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I bought some $BGMD undervalued play PT opinion is $1.45 - $1.55 short term expect coverage soon and others :)
11/19/12
Reply (3)

• !Report Abuse
View all 3 replies
Scott Matusow: u are welcome have a nice holiday
11/22/12
• !Report Abuse
EnderisLegend: you too brotha, and cant wait to see whos right on that $AVEO call
11/23/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I bought some $BGMD for a bounce - undervalued play PT opinion is $1.45 - $1.55 short term
11/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
BGMD - 48% Barchart technical sell signal - lost 15.57% in the last month - Relative Strength Index 37.98%
8/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
BGMD - 80% Barchart short tem, buy signal - 15 new highs and up 74.36% in the last month - Relative Strength Index 72.09%
6/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
$LGND $19.05 alerted at $16.60 $BGMD $1.35 alerted at $1.05 $AVEO $6.80 alerted at $6.60 $FOLD $4.85 alerted at $4.35
11/23/12
Reply (4)

• !Report Abuse
View all 4 replies
blakhalo: CPRX $.52 alerted at $1.88 -/+
11/26/12
• !Report Abuse
Scott Matusow: blak, u must lose money in the market -- I also gave a price target of $2.25 after financing -- that's on traders, now learn to make money
11/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$BGMD short term PT opinion call complete, $1.45 - $1.55 hit $1.58 today
11/23/12
Reply (2)

• !Report Abuse
View all 2 replies
sheldond: That was a pretty prescient call. Too bad I didn't put more on this oppotunity. Good Call!
11/24/12
• !Report Abuse
Scott Matusow: Thanks Sheldon --we all need more of these! Now I have to make sure I don't make bad calls, u know like the election prediction I made! lol!
11/24/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I bought some $BGMD undervalued play PT opinion is $1.45 - $1.55 short term expect coverage soon and others :)
11/19/12
Reply (3)

• !Report Abuse
View all 3 replies
Scott Matusow: u are welcome have a nice holiday
11/22/12
• !Report Abuse
EnderisLegend: you too brotha, and cant wait to see whos right on that $AVEO call
11/23/12
• !Report Abuse
Add a reply...

140 characters

BGMD BG Medicine, Inc.

BGMD

BG Medicine, Inc.